
Certara (CERT) Stock Forecast & Price Target
Certara (CERT) Analyst Ratings
Bulls say
Certara is likely to continue to accelerate medicines to patients using biosimulation software and technology, which could drive significant time and cost savings in drug discovery and development. The company has a strong presence in key markets and has reported strong production results, indicating success in its CIL and heap-leach circuits. Additionally, its recent divestiture of R&MW and focus on MIDD and AI-platform investments could contribute to improved growth and margin profiles for the company. While there are potential challenges such as competition and regulatory factors, Certara's strategic direction and potential catalysts, like the planned regional consolidation and drill program for its MDN project, support a positive outlook for the company.
Bears say
Certara is facing some challenges in achieving sustainable growth and improved profitability, as its near-term performance is highly dependent on the success of ramping growth and margin recovery in the second half of 2026. Additionally, concerns remain around the company's ability to drive consistent services revenue, and continued struggles in the Asian market may impact overall revenue growth. There is also the risk of passive selling pressure from potential removal from small-cap market indexes, which could negatively affect the company's stock value.
This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.
Certara (CERT) Analyst Forecast & Price Prediction
Start investing in Certara (CERT)
Order type
Buy in
Order amount
Est. shares
0 shares